Your browser doesn't support javascript.
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 27.956
Filtrar
10.
Zhonghua Yu Fang Yi Xue Za Zhi ; 54(1): 42-46, 2020 Jan 06.
Artigo em Chinês | MEDLINE | ID: mdl-31914568

RESUMO

Focusing on the current challenges and opportunities of China National Infectious Disease Surveillance Network (CNIDS), the exploration and development of pathogen detecting and tracing technologies, and the key issues in vaccine development, 48 experts from the disease control and prevention centers; research institutes, universities and hospitals launched an in-depth discussion on October 24-27, 2019, and reached the following consensus. (1) CNIDS needs to coordinate operational activities and to integrate data across governmental departments in order to build a human-centered and life-cycle based disease monitoring and health managing system. (2) In addition to standardize and further strengthen pathogen culturing and isolating techniques, it is desired to develop multi-targeted, ultra-sensitive, high-specific, high-throughput, digitalized and easy-to-use techniques for pathogen detections and pathobionts analyses. (3) The rapid development of pathogen tracing technologies calls to facilitate the formulation of a more efficient pathogen-tracing system by integrating technologies from genomics, bioinformatics and microbiology.(4) To strengthen the basic researches to support new vaccine developments, to explore vaccination strategies and to unfold the post-marketing evaluation on vaccines. Finally, experts proposed and discussed possiblecountermeasures and suggestions tackling with those challenges.


Assuntos
Pesquisa Biomédica , Consenso , Vigilância em Saúde Pública , Vacinas , China , Congressos como Assunto , Humanos
13.
Drugs Today (Barc) ; 55(11): 713-718, 2019 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-31840686

RESUMO

With 2019 shaping up to be another significant year for health economics and outcomes research, and increasingly innovative health technologies affecting both the cost and impact of healthcare decisions, rapid change is affecting healthcare systems in real time. The theme of this year's International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Europe annual meeting was centered on digital transformation of healthcare; over 4,000 attendees from over 90 countries spent the day in the discussion of the changing roles and shared responsibilities of increased digitization, which involves major changes not only in technology but also in the way care is organized and delivered.


Assuntos
Farmacoeconomia , Congressos como Assunto , Custos e Análise de Custo , Dinamarca
15.
Eur J Histochem ; 63(4)2019 Dec 23.
Artigo em Inglês | MEDLINE | ID: mdl-31868322

RESUMO

Histochemical techniques are widely applied in biomedical research and, during the last twenty years, they were among the methods used in more than 590,000 scientific articles in indexed journals. However, a very small percentage of these papers were published in strictly histochemical journals. A possible strategy to widen the audience of the histochemical journals making them attractive to non-histochemist authors might be to publish and make open-access available the proceedings of the meetings and conferences of valued scientific societies whose fellows use microscopy and histochemistry in their experimental activity. In the last years' experience of the European Journal of Histochemistry, this approach was effective to increase the number of published articles on stem cells and development, connective tissue and nerve cell biology.


Assuntos
Histocitoquímica , Jornalismo/organização & administração , Sociedades Científicas , Animais , Congressos como Assunto , Células do Tecido Conjuntivo/citologia , Neurônios/citologia , Células-Tronco/citologia
18.
HNO ; 67(12): 912-917, 2019 Dec.
Artigo em Alemão | MEDLINE | ID: mdl-31701169

RESUMO

At this year's Annual Meeting of the American Society for Clinical Oncology (ASCO), the keyword search "HPV-associated head and neck cancer" resulted in 920 hits-74% of the hits on human papillomavirus (HPV). This underlines the relevance of the topic. The spectrum ranged from validation and separation of the prognostic groups of patients with HPV-associated oropharyngeal carcinoma (OPSCC) according to TNM 8, to the characterization of new tumor markers and tumor mutational burden for possible de-escalation strategies to avoid toxicity of standard multimodal treatments. It has been shown that the separation of p16-positive OPSCC into Union for International Cancer Control (UICC) stages I and II with the current TNM 8 classification without further markers is not sufficiently successful to justify de-escalation strategies. Following publication of the results of the De-ESCALaTE- and RTOG-1016 trials in 2018, which confirm the current standard of care for p16-positive OPSCC, no further phase III studies on de-escalation were presented. In a presented prospective phase II study (NCT02281955), the radiotherapy dose was reduced to cumulative 60 Gy, whereby the simultaneous chemotherapy regimen with cisplatin 30 mg/m2 weekly is not standard of care and could be administered as an alternative to cisplatin cetuximab. Some work dealt with the oral and intestinal microbiota as prognostic markers or their treatment-related changes, particularly under immunotherapy. Modification seems to have a positive impact on the success of therapy. However, robust data are still lacking for the various modified treatments for HPV-associated OPSCC, which are needed before their implementation in daily practice.


Assuntos
Neoplasias de Cabeça e Pescoço , Neoplasias Orofaríngeas , Infecções por Papillomavirus , Congressos como Assunto , Neoplasias de Cabeça e Pescoço/virologia , Humanos , Oncologia , Neoplasias Orofaríngeas/virologia , Papillomaviridae , Infecções por Papillomavirus/complicações , Estudos Prospectivos , Estados Unidos
19.
HNO ; 67(12): 898-904, 2019 Dec.
Artigo em Alemão | MEDLINE | ID: mdl-31701170

RESUMO

BACKGROUND: The contributions presented at this year's ASCO conference on treatment of recurrent or metastatic head and neck squamous cell carcinoma (R/M-HNSCC) focused on systemic therapies, as in recent years. Two phase III studies-TPExtreme and Keynote-048-are expected to change clinical practice in first-line treatment of R/M-HNSCC. MATERIALS AND METHODS: Abstracts and presentations from this year's ASCO Annual Meeting on R/M-HNSCC were screened and checked for clinical relevance. RESULTS: TPExtreme, a randomized phase III trial, could show less toxicity and similar overall survival in patients treated with docetaxel, cisplatin, and cetuximab (TPEx regimen) compared to standard first-line therapy with the Extreme regimen (cisplatin, 5­fluorouracil [5-FU], cetuximab), albeit failing its endpoint of significantly improved survival. The randomized phase III Keynote-048 study could show a significant survival benefit in all patients treated with pembrolizumab, 5­FU, and cis-/carboplatin compared to Extreme. When selected patients (PD-L1 CPS ≥1 and ≥20) were treated with pembrolizumab monotherapy, they showed increased overall response rates in contrast to patients treated with Extreme. CONCLUSION: Based on the results of Keynote-048, pembrolizumab ± chemotherapy gained FDA approval as first-line treatment for R/M-HNSCC in the USA. Approval in Europe is expected soon and will probably have a strong impact on clinical routine.


Assuntos
Protocolos de Quimioterapia Combinada Antineoplásica , Neoplasias de Cabeça e Pescoço , Carcinoma de Células Escamosas de Cabeça e Pescoço , Cetuximab , Congressos como Assunto , Europa (Continente) , Neoplasias de Cabeça e Pescoço/tratamento farmacológico , Humanos , Recidiva Local de Neoplasia , Carcinoma de Células Escamosas de Cabeça e Pescoço/tratamento farmacológico
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA